Literature DB >> 15046385

Relationship between exhaled carbon monoxide and airway hyperresponsiveness in asthmatic patients.

Mayte Ramirez1, Francisco García-Río, Aleydis Viñas, Concepción Prados, José M Pino, José Villamor.   

Abstract

The study objectives were to analyze the changes in exhaled carbon monoxide (COex) induced by histamine provocation challenge in asthmatic patients and to evaluate the relationship between COex and airway sensitivity and reactivity. Levels of COex were measured in 105 nonsmoking mildly asthmatic subjects before and after histamine provocation challenge. Dose-response curves were characterized by their sensitivity (PD20) and reactivity. Dose-response slope (DRS), continuous index of responsiveness (CIR), and bronchial reactivity index (BRI) were determined as reactivity indices. Bronchial challenge was positive for 47 subjects and negative for 58. The COex levels rose significantly after bronchial challenge in the positive response group (4.49 +/- 0.4 vs. 5.74 +/- 0.57 ppm, p = 0.025) and in the negative response group (2.84 +/- 0.25 vs. 4.00 +/- 0.41 ppm, p = 0.000). An inverse relation between basal COex and PD20 was found (r = -0.318, p = 0.030). In all subjects, a proportional direct relationship between COex and DRS (r = 0.214, p = 0.015), CIR (r = 0.401, p = 0.000), and BRI (r = 0.208, p = 0.012) was observed. On stepwise multiple linear regression analysis, COex only significantly correlated with CIR (multiple r2 = 0.174, p = 0.000). In conclusion, exhaled CO determination is a noninvasive inflammatory marker of the respiratory tract, which shows an acceptable association with airway hyperresponsiveness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046385     DOI: 10.1081/jas-120026068

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  1 in total

1.  Serum concentration of C-reactive protein is not a good marker of bronchial hyperresponsiveness.

Authors:  Bernard Panaszek; Ewa Liebhart; Jerzy Liebhart; Robert Pawłowicz; Andrzej M Fal
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Sep-Oct       Impact factor: 4.291

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.